New Coronavirus Variant ‘Stratus' Noted for Mild Symptoms
In the Southeast Asia region, a new coronavirus variant called XFG, or 'Stratus,' is gaining momentum.1 The World Health Organization currently assesses the health risk from 'Stratus' as low. Approved vaccines are expected to remain effective against severe illness. However, as the spread of 'Stratus' increases globally and several Southeast Asian countries report a rise in new cases and hospitalizations, the WHO has classified it as a 'variant under monitoring.'1 FITBOOK explains what doctors have reported about the symptoms so far and how the virus is currently spreading in Germany.
XFG ('Stratus') is a SARS-CoV-2 variant that has emerged from the LF.7 and LP.8.1.2 lineages. Despite the rapid spread of this variant, there is currently no evidence that 'Stratus' causes more severe illness than other circulating variants.
In previous COVID-19 waves, loss of taste and smell were characteristic symptoms. For 'Nimbus,' first detected in Germany at the end of March and currently responsible for 60 percent of COVID-19 infections according to the Robert Koch Institute, it was the 'razor blade-like sore throat.'2 What are the specific symptoms of 'Stratus'?
The WHO risk report contains no information on the symptoms of 'Stratus' (XFG). Nor are there any official statements from national health authorities on specific symptoms of this new variant. However, various media sources, particularly from India, report observations from doctors. A notable feature of the current wave is the frequent reporting of hoarseness in COVID patients, as reported by the 'Times of India' on May 30.3 Many patients this time are complaining of 'dry or irritated cough, accompanied by sore throat and hoarseness.' Doctors from various hospitals have confirmed that hoarseness is now a common symptom in clinics across India. Hoarseness manifests as a scratchy or rough voice.
Also interesting: 9 new COVID symptoms added to the official list
Because 'Stratus,' like the other currently globally dominant variant 'Nimbus,' has the potential to trigger a COVID wave, the choice fell on another meteorological term for cloud types – 'Stratus' – said virologist Dr. Ryan Gregory to the website Gavi.org.4 The organization Gavi is one of the world's key players in vaccination programs. Virologist Gregory is part of a network of researchers that assigns unofficial nicknames to new virus variants.
'The Sun,' a British tabloid, refers to 'Stratus' as the 'Frankenstein Variant' because it resulted from the combination of two different COVID-19 strains.5 This occurs when a person is simultaneously infected with two different variants, which then merge into a new hybrid variant.
Participate in our FITBOOK survey!
According to virologist Gregory, 'Nimbus' and 'Stratus' are currently competing for dominance worldwide. Despite their rapid spread, there is currently no evidence that 'Stratus' (XFG) or 'Nimbus' (NB.1.8.1) cause more severe illness than other circulating variants. According to 'Gavi,' both variants have mutated spike proteins. This means they may be better able to evade immunity built up from previous infections or vaccinations. In other words, this likely makes it harder for the immune system to recognize and combat the virus.
Also interesting: Largest study to date on COVID vaccinations identifies potential follow-up illnesses
The spread of 'Stratus' is still in its early stages in Europe, with the WHO reporting it at around 16 percent in the region. In England, the share of XFG rose from 10 percent in May to 40 percent by mid-June 2025. In Germany, 'Stratus' last appeared in the Robert Koch Institute's statistics on coronavirus variants in early June, with a percentage share of 5.56 percent; the week before, this share was 8.33 percent. The highest percentage recorded for 'Stratus' (XFG) was in mid-May 2025. Currently, 'Nimbus' dominates in Germany (60 percent). The situation is developing dynamically, so continuous monitoring remains important.
Even though XFG has the highest relative growth advantage among the current lineages, the WHO currently sees no evidence of more severe illness or atypical clinical patterns. Approved vaccines continue to protect against symptomatic and severe cases, according to the risk paper on 'Stratus.'
The post New Coronavirus Variant 'Stratus' Noted for Mild Symptoms appeared first on FITBOOK.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
2 hours ago
- UPI
CDC director: Misinformation 'lead to deadly consequence" in Atlanta
The U.S. Centers for Disease Control and Prevention headquarters in Atlanta was attacked by a gunman on Friday. File Photo by Erike S. Lesser/EPA Aug. 13 (UPI) -- The director of the Centers for Disease Control and Prevention told employees about the dangers of misinformation, four days after a suspected gunman shot at the agency's headquarters in Atlanta, claiming the COVID-19 vaccine made him sick. On Tuesday, Susan Monarez met with staffers virtually and then sent a note to all 10,000 employees nationwide, obtained by ABC News. Staffers at the headquarters have been working remotely since the attack on Friday. "The dangers of misinformation and its promulgation has now led to deadly consequences," she wrote. "I will work to restore trust in public health to those who have lost it -- through science, evidence and clarity of purpose. I will need your help." The comments were slightly different than those during her staff meeting in which she said: "Public health should never be under attack. We know that misinformation can be dangerous." She said the health agency can rebuild trust with "rational evidence-based discourse" with "compassion and understanding." Dr. Paul Offit, the director of the Vaccine Education Center at Children's Hospital of Pennsylvania, told NBC News: "The irony is her boss is the biggest spreader of misinformation." Robert F. Kennedy Jr. is secretary of the Health and Human Services, which oversees the CDC. In 2021, during the pandemic, Kennedy described the shot as the "deadliest vaccine ever made" after he filed a citizens' petition requesting that the Food and Drug Administration end emergency authorization. Last week, Kennedy announced that HHS was moving to terminate $500 million in contracts to develop vaccines using mRNA technology, which was used to develop the COVID-19 vaccine in 2020. "After reviewing the science and consulting top experts at NIH [National Institutes of Health] and FDA, HHS has determined that mRNA technology poses more risks than benefits for these respiratory viruses," The American Medical Association backs mRNA vaccine research and the CDC still says on its website: "During the COVID-19 pandemic, COVID-19 vaccines underwent the most intensive safety analysis in U.S. history." Health officials have denounced skepticism of the research, noting the COVID-19 vaccine saved millions of lives in the United States. "The Covid pandemic showed us what's possible when science moves fast," Rick Bright, who directed the Biomedical Advanced Research and Development from 2016 to 2020, told NBC News. "Dismantling that momentum now is like disbanding the fire department because the fire's out." As head of the HHS, he has updated COVID-19 vaccine recommendations for the fall to be restricted to older adults and those with underlying health conditions. He also doesn't want children to get the shots. On Monday, Kennedy toured the CDC campus in Atlanta and met with the widow of the one person slain in the attack, DeKalb County Police Officer David Rose. He toured with Monarez and HHS Deputy Secretary Jim O'Neill. "He offered his deepest condolences and reaffirmed the agency's commitment to honoring officer Rose's bravery, sacrifice and service to the nation," HHS said. Today I traveled to Atlanta in the wake of the heartbreaking shooting at the CDC's Roybal Campus that took the life of DeKalb County Police Officer David Rose. @POTUS and the entire administration are deeply saddened by this tragic loss. We stand with Officer Rose's wife, his two... Secretary Kennedy (@SecKennedy) August 11, 2025 Since the attack, the union representing CDC workers condemned the lack of support from top officials. "This leadership is critical in reinforcing public trust and ensuring that accurate, science-based information prevails," the union said Sunday. "This condemnation is necessary to help prevent violence against scientists that may be incited by such disinformation." The American Federation of Government Employees Local 2883, which represents more than 2,000 CDC workers, said in a statement Sunday that the attack "was not random and it compounds months of mistreatment, neglect and vilification that CDC staff have endured." The union also said: "The deliberate targeting of CDC through this violent act is deeply disturbing, completely unacceptable and an attack on every public servant." The father of the suspected gunman, 30-year-old Patrick Joseph White, reportedly told authorities he targeted the CDC over health problems he blamed on the COVID-19 vaccine. He said the shot made him depressed and suicidal. He was fatally shot by police after around 200 bullets struck the six buildings. Five firearms were recovered. "All indications are that this was an isolated event involving one individual," Jeff Williams, the deputy secretary of the CDC's Office of Safety, Security and Asset Management, said during the staff meeting Tuesday.
Time Business News
4 hours ago
- Time Business News
Hygiene Tech Meets Healing Proteins
Hospital-acquired infections can be caused by the cross-infection from surface and skin of patient, equipment, and healthcare staff. Various types of products and services are available to control hospital-acquired infections such as sterilization, cleaning & disinfection products, protective barriers, and endoscope reprocessing products. Increase in awareness regarding personal hygiene after COVID-19 is a major factor to boost the Hospital Infection Prevention and Control growth. Growth factors, proteins or peptides found in nature, are important for the control of cell actions like growth, specialization, movement, and survival. They attach to certain receptors on cell surfaces, which starts signals inside the cells that change how they act. Growth factors are needed for body functions such as development in embryos, healing wounds, fixing tissues, and immune reactions. Key Growth Drivers and Opportunities High Cases of Hospital Acquired Infections: Hospital-acquired infections (HAIs) remain a major risk to patient safety and healthcare results around the world. These infections, often caused by bacteria like Staphylococcus aureus, Clostridium difficile, and Escherichia coli, usually happen because of long hospital stays, surgeries, poor infection control, and antibiotic resistance. Those in intensive care, people with weak immune systems, and those having surgery are at risk. HAIs raise sickness and death rates; these also cause higher medical costs and longer stays in hospitals. Growing Geriatric Population: The growing geriatric population significantly contributes to the rise in hospital-acquired infections, as older adults often have weakened immune systems and require frequent medical care or hospitalization. This increases their vulnerability to infections, driving the demand for effective hospital infection prevention and control measures. As a result, healthcare facilities are investing more in disinfection, protective equipment, and sterilization solutions to ensure patient safety and reduce infection risks in aging populations. Challenges Failure of end-users to follow infection prevention rules limits how well hospital infection control works. When staff, patients, or support people don't follow hygiene rules—such as washing hands, sterilizing tools, or using safety gear— the risk of contamination and infections rises. Innovation and Expansion NAVTA & Virox Launch Free Infection Control Training for Safer Vet Care In March 2023, (National Association of Veterinary Technicians in America) NAVTA, Virox launch certificate program in infection prevention, to advance best practices in infection prevention. This program is a free online program designed to provide professionals with the knowledge needed to reduce the risk of spreading infection and create a safer workplace for their team, patients, and clients. NeoIPC Unveils Toolkit to Shield Newborns from Hospital Infections In November 2023, The NeoIPC Consortium announced the launch of a new surveillance toolkit to help neonatal intensive care units (NICUs) track and prevent hospital-acquired infections (HAIs) in high-risk newborns, including very preterm infants. This toolkit aims to standardize how infections are tracked in Newborn Intensive Care Units (NICUs) to allow for improved data gathering and assessment. It has tools, training, and reporting forms made for newborn care locations. By helping with early detection and response, this project hopes to lower infection rates and improve results for fragile newborns. Inventive Sparks, Expanding Markets The key players operating the hospital infection prevention and control market includes, 3M Company, Crosstex International, Inc., Johnson & Johnson, Belimed AG, among others. Worldwide business aims center on encouraging lasting growth, improving health and safety for the public, and boosting progress through cooperation. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
USA Today
8 hours ago
- USA Today
FDA may revoke Pfizer COVID-19 shot for young, healthy children.
Parents won't be able to vaccinate their healthy children 6 months to 5 years old if the FDA pulls Pfizer's COVID-19 vaccine authorization. The Food and Drug Administration may revoke authorization for Pfizer's COVID-19 vaccine for healthy children under age 5, the pharmaceutical company confirmed, which would limit parents' vaccine options ahead of the winter respiratory virus season. The possibility comes several months after President Donald Trump's Department of Health and Human Services began placing limits on COVID-19 vaccines. For the last four years, updated COVID-19 vaccines have been made available in the fall for most Americans before the cold sets in. The federal agency told Pfizer that it might not renew the emergency use authorization, or EUA, for the Pfizer-BioNTech COVID-19 vaccine Comirnaty for children ages 6 months through 4 years, according to a statement sent to USA TODAY. 'We are currently in discussions with the agency on potential paths forward and have requested that the EUA for this age group remain in place for the 2025-2026 season,' a company spokesperson said. 'It is important to note that these deliberations are not related to the safety and efficacy of the vaccine, which continues to demonstrate a favorable profile.' HHS spokesperson Andrew Nixon declined to predict what the agency might do. 'We do not comment on potential, future regulatory changes,' Nixon said. 'Unless officially announced by HHS, discussion about future agency action should be regarded as pure speculation.' In July, Moderna received full FDA approval for its COVID-19 vaccine for children 6 months to 11 years old who are at increased risk of contracting COVID-19. The vaccine, Spikevax, is expected to be available for eligible populations in the 2025-26 respiratory virus season. The Centers for Disease Control and Prevention still recommends older patients get vaccinated against COVID-19, as well as people whose immune systems have been weakened by illness or medical treatments such as chemotherapy. But if Pfizer loses its EUA, parents won't have the option to vaccinate their healthy young children. HHS Secretary Robert F. Kennedy Jr. has long sown doubt about a wide range of vaccines, while saying parents should be able to choose which vaccines their children should get. In late May, he announced that the COVID-19 vaccine for healthy children and healthy pregnant women was removed from the Centers for Disease Control and Prevention's immunization schedule. 'There's no evidence healthy kids need it today," Dr. Marty Makary, FDA commissioner, said in the May 27 video announcement posted to X. The American Academy of Pediatrics pushed back, saying at the time that the removal 'ignores independent medical experts and leaves children at risk.' Ending access to vaccination for healthy young children would strip families of choice, said Dr. Sean O'Leary, chair of the academy's committee on infectious diseases, in a May statement. 'Those who want to vaccinate may no longer be able to, as the implications for insurance coverage and access remain unclear," he said.
